Dr Andrew Nash: Ledger

Role	Organisation	Sources
	Brandon BioCatalyst	Brandon BioCatalyst, Brandon BioCatalyst team page
Chief Scientific Officer and Global Head of Research (former)	CSL	Brandon BioCatalyst, @AuManufacturing, Brandon BioCatalyst portfolio, Brandon Capital portfolio, Startup Daily

Coverage

Stories naming Dr Andrew Nash. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Fund close $439m

Peter Beattie AC appointed Brandon BioCatalyst Chair

Brandon BioCatalyst has named Peter Beattie its chair as Bill Ferris retires, with Andrew Nash joining the board and Ross King becoming deputy; manager Brandon Capital's newly raised $439 million fund was noted.

Brandon BioCatalyst portfolio Tue 19 Aug 2025 Brandon Capital Australian Institute for Bioengineering and Nanotechnology Brandon BioCatalyst Burnet Institute Citigroup CSL Goldman Sachs Australia Institute for Molecular Bioscience University of Queensland Vicebio NRF Corporation Dr Andrew Nash Bill Ferris AC Dr Chris Nave Peter Beattie AC Ross King

Grant $1m

Calix and CSL in Victorian biotechnology developments

Calix received a $1 million federal grant for its Bacchus Marsh biotech operations, while CSL is dedicating floors of its new Melbourne headquarters to a biotechnology incubator with university and research institute partners.

@AuManufacturing Wed 30 Jun 2021 Calix CSL Melbourne University Modernisation Manufacturing Fund WEHI Dr Andrew Nash Dr Phil Hodgson

Series A $14m

$14m invested in University of Melbourne spin-out to create vaccine for periodontal gum disease

A biotech spin-out from the University of Melbourne has raised a Series A to develop a gum disease vaccine, backed by a biomedical translation fund, a large biotech company and the university itself.

Brandon Capital portfolio Thu 26 Sep 2019 Denteric Brandon Capital Partners Centre for Oral Health Research (COHR)Cooperative Research Centres Program Medical Research Commercialisation Fund (MRCF)Melbourne Dental School Oral Health CRC Victorian Government Australian Government Biomedical Translation Fund CSL University of Melbourne Dr Andrew Nash Dr Chris Nave Professor Eric Reynolds AO Professor Jim McCluskey

Also Brandon BioCatalyst portfolio·Startup Daily·denteric.com·denteric.com·@AuManufacturing·Startup Daily

Dr Andrew Nash

Roles

Coverage

Peter Beattie AC appointed Brandon BioCatalyst Chair

Calix and CSL in Victorian biotechnology developments

$14m invested in University of Melbourne spin-out to create vaccine for periodontal gum disease